235 related articles for article (PubMed ID: 30324582)
1. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention.
Guo X; Han T; Hu P; Guo X; Zhu C; Wang Y; Chang S
Int Urol Nephrol; 2018 Dec; 50(12):2193-2200. PubMed ID: 30324582
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
4. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
Zhang HL; Qin XJ; Cao DL; Zhu Y; Yao XD; Zhang SL; Dai B; Ye DW
Asian J Androl; 2013 Mar; 15(2):231-5. PubMed ID: 23377530
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
6. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
7. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
8. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
9. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Wach S; Al-Janabi O; Weigelt K; Fischer K; Greither T; Marcou M; Theil G; Nolte E; Holzhausen HJ; Stöhr R; Huppert V; Hartmann A; Fornara P; Wullich B; Taubert H
Int J Cancer; 2015 Sep; 137(6):1406-16. PubMed ID: 25754273
[TBL] [Abstract][Full Text] [Related]
10. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Paschoal AR; Rogatto SR; Cólus IMS
PLoS One; 2017; 12(9):e0184094. PubMed ID: 28910345
[TBL] [Abstract][Full Text] [Related]
11. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
13. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
14. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
15. High-Level Expression of microRNA-21 in Peripheral Blood Mononuclear Cells Is a Diagnostic and Prognostic Marker in Prostate Cancer.
Huang W; Kang XL; Cen S; Wang Y; Chen X
Genet Test Mol Biomarkers; 2015 Sep; 19(9):469-75. PubMed ID: 26247873
[TBL] [Abstract][Full Text] [Related]
16. Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer.
Peng P; Chen T; Wang Q; Zhang Y; Zheng F; Huang S; Tang Y; Yang C; Ding W; Ren D; Huang Z; Guo Y
Oncol Res Treat; 2019; 42(4):165-185. PubMed ID: 30870834
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract][Full Text] [Related]
18. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
[TBL] [Abstract][Full Text] [Related]
19. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
20. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
